We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+8.42%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$353M
AUM Growth
-$134M
(-28%)
Cap. Flow
-$160M
Cap. Flow
% of AUM
-45.25%
Top 10 Holdings %
Top 10 Hldgs %
53.01%
Holding
85
New
13
Increased
11
Reduced
25
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Henry Schein
HSIC
|
+$15.5M |
| 2 |
Cigna
CI
|
+$8.74M |
| 3 |
AdaptHealth
AHCO
|
+$8.55M |
| 4 |
Viatris
VTRS
|
+$8.32M |
| 5 |
UnitedHealth
UNH
|
+$7.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$19.6M |
| 2 |
HOLX
Hologic
HOLX
|
+$18.4M |
| 3 |
Quest Diagnostics
DGX
|
+$17.7M |
| 4 |
LMNX
Luminex Corp
LMNX
|
+$15.3M |
| 5 |
RadNet
RDNT
|
+$12.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.67% |
| 2 | Consumer Staples | 5.19% |
| 3 | Consumer Discretionary | 1.58% |
| 4 | Technology | 0.36% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Medtronic
MDT
$107B
| $31M | 8.79% |
250,000
-50,000
| -17% | -$6.28M |
|
2
Rigel Pharmaceuticals
RIGL
$680M
| $27.8M | 7.87% |
640,000
-195,000
| -23% | -$7.36M |
|
|
3
Henry Schein
HSIC
$9.74B
| $23.4M | 6.62% |
315,000
+205,000
| +186% | +$15.5M |
|
4
Pacira BioSciences
PCRX
$1.02B
| $21.8M | 6.19% |
360,000
-190,000
| -35% | -$12M |
|
5
Turning Point Brands
TPB
$1.47B
| $18.3M | 5.19% |
400,000
| – | – |
|
|
PDCO
6
DELISTED
Patterson Companies, Inc.
PDCO
| $14.4M | 4.09% |
475,000
-295,000
| -38% | -$9.94M |
|
|
VRAY
7
DELISTED
ViewRay, Inc.
VRAY
| $13.2M | 3.74% |
2,000,000
-450,000
| -18% | -$2.4M |
|
8
Integer Holdings
ITGR
$3.35B
| $12.7M | 3.6% |
135,000
+5,200
| +4% | +$479K |
|
9
Lantheus
LNTH
$6.82B
| $12.4M | 3.52% |
450,000
-475,000
| -51% | -$10.9M |
|
|
10
UnitedHealth
UNH
$382B
| $12M | 3.4% |
30,000
+20,000
| +200% | +$7.97M |
|
11
AtriCure
ATRC
$1.77B
| $11.9M | 3.37% |
150,000
-50,000
| -25% | -$3.63M |
|
|
12
Viatris
VTRS
$20.1B
| $11.8M | 3.34% |
825,000
+575,000
| +230% | +$8.32M |
|
13
United Therapeutics
UTHR
$26.3B
| $11.1M | 3.15% |
62,000
-38,000
| -38% | -$7.24M |
|
|
STRM
14
DELISTED
Streamline Health Solutions
STRM
| $8.73M | 2.47% |
328,725
| – | – |
|
15
Bioventus
BVS
$799M
| $8.36M | 2.37% |
475,000
-200,000
| -30% | -$3.22M |
|
16
CVS Health
CVS
$137B
| $8.34M | 2.36% |
100,000
-125,000
| -56% | -$10.2M |
|
|
MDRX
17
DELISTED
Veradigm Inc. Common Stock
MDRX
| $8.33M | 2.36% |
450,000
-425,000
| -49% | -$7.15M |
|
|
MSON
18
DELISTED
Misonix Inc
MSON
| $8.32M | 2.36% |
375,000
+25,000
| +7% | +$510K |
|
|
19
Cigna
CI
$76.6B
| $8.3M | 2.35% |
+35,000
| New | +$8.74M |
|
|
20
AdaptHealth
AHCO
$1.46B
| $8.22M | 2.33% |
+300,000
| New | +$8.55M |
|
21
AngioDynamics
ANGO
$562M
| $8.14M | 2.31% |
300,000
-25,000
| -8% | -$611K |
|
22
SI-BONE Inc
SIBN
$737M
| $8.03M | 2.27% |
255,000
-20,000
| -7% | -$647K |
|
|
23
RadNet
RDNT
$4.84B
| $7.58M | 2.15% |
225,000
-460,000
| -67% | -$12.1M |
|
24
ICU Medical
ICUI
$3.93B
| $7M | 1.98% |
34,000
-36,000
| -51% | -$7.41M |
|
25
Phreesia
PHR
$632M
| $6.85M | 1.94% |
+111,800
| New | +$5.82M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, Tamarack Advisers held 85 positions worth $353M, down 28% from $488M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Tamarack Advisers withdrew a net $160M in Q2 2021, closing 34 positions and reducing 25 holdings. Its most notable exit was Hologic, an estimated $18.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 85% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, Tamarack Advisers opened a new position in Cigna worth $8.3M.
- Tamarack Advisers's largest Q2 2021 buy was Cigna: 35,000 shares worth $8.3M.
- Tamarack Advisers added most to Henry Schein in Q2 2021, an estimated $15.5M increase.
- Tamarack Advisers's biggest Q2 2021 reduction was Labcorp, cutting an estimated $19.6M.
- Tamarack Advisers fully exited Hologic in Q2 2021, selling an estimated $18.4M.
- Tamarack Advisers's ten largest holdings make up 53% of its $353M portfolio in Q2 2021.
- Tamarack Advisers opened 13 new positions and closed 34 in Q2 2021.
- Tamarack Advisers's portfolio value fell 28% quarter-over-quarter to $353M.
Based on Tamarack Advisers's 13F filing for Q2 2021, filed 13 Aug 2021.